Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

RiKen Institute

http://www.riken.jp/en/

Latest From RiKen Institute

Asia Deal Watch: Astellas Looks To Vector Cell Tech From Japan’s RiKen In Oncology

RiKen gets $9.3m up front plus potential milestones and royalties for use of its aAVC technology, while retaining research rights to the platform. JW Pharmaceutical acquires Vietnam’s Euvipharm.

Deals Business Strategies

First iPS Cell Trial Underway But A Long Way To Go

Researchers in Japan have "dosed" the initial patient in the world's first clinical trial involving a regenerative therapy based on the country's flagship induced pluripotent stem (iPS) cell technology.

BioPharmaceutical Japan

Life Science Start-Ups: Tech Transfer Deals, February 2014

Derived from Strategic Transactions, a fully searchable premium source for tracking life sciences deal activity, the Tech Transfer Deals column provides a monthly update on technology transfer deals, reporting licensing agreements between companies and universities or other research institutions within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced December 2013 through January 2014.

BioPharmaceutical Medical Device

Regenerative Medicine Policy In Japan Could Serve As Global Breeding Ground For New Technologies

Japan’s evolving policy on regenerative medicine approval and safety could create a gateway for global market entry.

BioPharmaceutical Japan
See All
Advertisement
Advertisement
UsernamePublicRestriction

Register